One DNA Methylation Regulates CHIP Gene Expression of Human Breast Cancer and Predicts Recurrence

Background/Aim: Carboxyl terminus of Hsc70-interacting protein (CHIP) is a ubiquitin ligase that induces ubiquitination and degradation of its target proteins including oncoproteins. We reported that its down-regulation is associated with tumor progression and metastasis of breast cancer. However, the mechanism through which CHIP gene affects cancer cells is unclear. Materials and Methods: We extracted RNA from 45 primary breast cancer samples and compared CHIP mRNA expression profiles, promoter DNA methylation status, and clinicopathological information. Results: CHIP mRNA expression was significantly correlated with the tumor progression status. In several samples, a pinpoint CpG methylation in the CHIP gene promoter region was significantly correlated with CHIP mRNA expression. When this specific CpG was methylated in estrogen receptor (ER)-positive cases, a significant difference in 5-year recurrence was not found compared with ER-negative cases. Conclusion: CpG methylation contributes to the long-term prognosis of ER-positive breast cancer.

[1]  Nobuhiro Nakamura,et al.  Ubiquitin System , 2018, International journal of molecular sciences.

[2]  M. Kurosumi,et al.  Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  M. Kurosumi,et al.  Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70‐interacting protein in postmenopausal breast cancer , 2016, Cancer medicine.

[4]  H. Kliem,et al.  A differentially methylated single CpG-site is correlated with estrogen receptor alpha transcription , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  F. Talos,et al.  Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells , 2011, Molecular Cancer Research.

[6]  J. Griggs,et al.  American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of oncology practice.

[7]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[8]  S. Hayashi,et al.  Estrogen signaling pathway and its imaging in human breast cancer , 2009, Cancer science.

[9]  M. Kurosumi,et al.  The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways , 2009, Nature Cell Biology.

[10]  T. Bestor,et al.  The Colorful History of Active DNA Demethylation , 2008, Cell.

[11]  T. Clouaire,et al.  Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? , 2008, Cellular and Molecular Life Sciences.

[12]  E. Winer,et al.  Advances in adjuvant endocrine therapy for postmenopausal women. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Reik.  Stability and flexibility of epigenetic gene regulation in mammalian development , 2007, Nature.

[14]  K. Nephew,et al.  CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. , 2005, Molecular endocrinology.

[15]  M. Scheffner,et al.  The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation* , 2005, Journal of Biological Chemistry.

[16]  S. Kato,et al.  Ligand‐dependent switching of ubiquitin–proteasome pathways for estrogen receptor , 2004, The EMBO journal.

[17]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[18]  K. Tanimoto,et al.  The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. , 2003, Endocrine-related cancer.

[19]  L. Neckers,et al.  Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[21]  P. Connell,et al.  Identification of CHIP, a Novel Tetratricopeptide Repeat-Containing Protein That Interacts with Heat Shock Proteins and Negatively Regulates Chaperone Functions , 1999, Molecular and Cellular Biology.

[22]  J. Daurès,et al.  Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause , 1998, Cancer.

[23]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[24]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[25]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[26]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[27]  A. Tsimokha,et al.  Role of proteasomes in cellular regulation. , 2008, International review of cell and molecular biology.

[28]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[29]  P. Connell,et al.  The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins , 2000, Nature Cell Biology.

[30]  D. Cyr,et al.  The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation , 2000, Nature Cell Biology.

[31]  M. Hochstrasser.  Ubiquitin-dependent protein degradation. , 1996, Annual review of genetics.